Delving into the Latest Updates on MEDI-8852 with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Target

hemagglutinin

Action

modulators

Mechanism

hemagglutinin modulators(Influenza virus hemagglutinin glycoproteins modulators)

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

Influenza, Human

Inactive Indication

Influenza A virus infection

Originator Organization

Humabs BioMed SA

Active Organization

Humabs BioMed SA

Inactive Organization

MedImmune LLC

AstraZeneca PLC

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Sequence Code 173981L

Sequence Code 4730175H

The purposes of this study are to determine if MEDI8852 administered with standard of care (oseltamivir) will reduce the time to normalization of respiratory function for adults who are hospitalized with influenza caused by Type A strains and to determine if MEDI8852 has an acceptable safety profile in adults who are hospitalized with influenza caused by Type A strains.

Start Date24 Jul 2017

Sponsor / Collaborator

MedImmune LLC

EUCTR2015-004276-29-BE

/ Not yet recruitingPhase 2

A Phase 2b, Randomized, Double-blind, Single-dose, Active-controlled,Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 inAdults who are Hospitalized with Influenza Caused by Type A Strains

Start Date02 Feb 2017

Sponsor / Collaborator

MedImmune LLC

100 Clinical Results associated with MEDI-8852

Login to view more data

100 Translational Medicine associated with MEDI-8852

Login to view more data

100 Patents (Medical) associated with MEDI-8852

Login to view more data

8

Literatures (Medical) associated with MEDI-8852

01 Mar 2025·Structure

Computational design and improvement of a broad influenza virus HA stem targeting antibody

Article

Author: Yang, Wei ; Gao, Peixiang ; Zhang, Fangyuan ; Pan, Shengnan ; Liao, Yi ; Yang, Xuehua ; Dong, Xuemeng ; Duan, Huarui ; Zhang, Xinhui ; Liu, Xiuying ; Chi, Xiaojing

Broadly neutralizing antibodies (nAbs) are vital therapeutic tools to counteract both pandemic and seasonal influenza threats. Traditional strategies for optimizing nAbs generally rely on labor-intensive, high-throughput mutagenesis screens. Here, we present an innovative structure-based design framework for the optimization of nAbs, which integrates epitope-paratope analysis, computational modeling, and rational design approaches, complemented by comprehensive experimental assessment. This approach was applied to optimize MEDI8852, a nAb targeting the stalk region of influenza A virus hemagglutinin (HA). The resulting variant, M18.1.2.2, shows a marked enhancement in both affinity and neutralizing efficacy, as demonstrated both in vitro and in vivo. Computational modeling reveals that this improvement can be attributed to the fine-tuning of interactions between the antibody's side-chains and the epitope residues that are highly conserved across the influenza A virus HA stalk. Our dry-wet iterative protocol for nAb optimization presented here yielded a promising candidate for influenza intervention.

31 Jan 2025·Science

Pre-exposure antibody prophylaxis protects macaques from severe influenza

Article

Author: Graham, Barney S. ; Cooper, Kristine ; Mascola, John R. ; Lipinski, Abby ; Perez, Daniel R. ; Treat, Benjamin R. ; Kanekiyo, Masaru ; Loo, Yueh-Ming ; Walker, Reagan ; Lundy, Jeneveve ; Kettenburg, Gwenddolen ; Gillespie, Rebecca A. ; Reed, Douglas S. ; Olsen, Emily ; Treaster, Luke ; Castanha, Priscila M. S. ; Esser, Mark ; Canedo, Vanessa Guerra ; Laughlin, Amanda ; Creanga, Adrian ; Yang, Eun Sung ; Corry, Jacqueline ; Ritter, Isabella ; Barrick, Stacey ; Midgett, Morgan ; Pegu, Amarendra ; Martí, Michelle M. ; O’Malley, Katherine ; Boritz, Eli A. ; Chavva, Hasitha ; Batsche, Lucia Ortiz ; Williams, Connor ; Yun, Gabin ; Wallace, Megan ; Barratt-Boyes, Simon M. ; Blair, Wade

Influenza virus pandemics and seasonal epidemics have claimed countless lives. Recurrent zoonotic spillovers of influenza viruses with pandemic potential underscore the need for effective countermeasures. In this study, we show that pre-exposure prophylaxis with broadly neutralizing antibody (bnAb) MEDI8852 is highly effective in protecting cynomolgus macaques from severe disease caused by aerosolized highly pathogenic avian influenza H5N1 virus infection. Protection was antibody dose–dependent yet independent of Fc-mediated effector functions at the dose tested. Macaques receiving MEDI8852 at 10 milligrams per kilogram or higher had negligible impairment of respiratory function after infection, whereas control animals were not protected from severe disease and fatality. Given the breadth of MEDI8852 and other bnAbs, we anticipate that protection from unforeseen pandemic influenza A viruses is achievable.

25 Jul 2019·JCI InsightQ1 · MEDICINE

Survival during influenza-associated bacterial superinfection improves following viral- and bacterial-specific monoclonal antibody treatment

Q1 · MEDICINE

ArticleOA

Author: Tobin, Joshua M ; Ramanan, Krishnaveni ; Sellman, Bret R ; Robinson, Keven M ; Nickolich, Kara L ; Alcorn, John F ; Pilewski, Matthew J ; Cohen, Taylor S ; Kallewaard, Nicole L

Postinfluenza bacterial superinfections cause increased morbidity and mortality compared with singular infection with influenza during both pandemics and seasonal epidemics. Vaccines and current treatments provide limited benefit, a rationale to conduct studies utilizing alternative therapies. FY1 and an optimized version, MEDI8852, anti-influenza HA mAbs, have been shown to neutralize influenza virus during singular influenza infection. MEDI4893*, an anti-Staphylococcus aureus α-toxin mAb, has been shown to improve survival when administered prophylactically prior to S. aureus pneumonia. Our objective was to determine if mAbs can improve survival during postinfluenza bacterial pneumonia. We administered FY1 in a murine model of postinfluenza methicillin-resistant S. aureus (MRSA) pneumonia and observed improved survival rates when given early during the course of influenza infection. Our findings indicate decreased lung injury and increased uptake and binding of bacteria by macrophages in the mice that received FY1 earlier in the course of influenza infection, corresponding to decreased bacterial burden. We also observed improved survival when mice were treated with a combination of FY1 and MEDI4893* late during the course of postinfluenza MRSA pneumonia. In conclusion, both FY1 and MEDI4893* prolong survival when used in a murine model of postinfluenza MRSA pneumonia, suggesting pathogen-specific mAbs as a possible therapeutic in the context of bacterial superinfection.

100 Deals associated with MEDI-8852

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Influenza, Human	Phase 2	-	Humabs BioMed SA	-
Influenza A virus infection	Preclinical	United States	AstraZeneca PLC	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02603952 (Pubmed \| Antimicrob Agents Chemother) Manual	Phase 1/2	Influenza A virus infection	126	oseltamivir+MEDI8852	hwplguwlks(czveqjgtls) = anlmbsyjtw ungyjhysxk (ohemppzvew ) View more	Positive	24 Oct 2018
				Placebo+oseltamivir	hwplguwlks(czveqjgtls) = piaokzfwyz ungyjhysxk (ohemppzvew ) View more
NCT02603952 (MEDI8852, CTgov)	Phase 1/2	Influenza, Human	126	Placebo+Oseltamivir (Placebo + Oseltamivir 75 mg)	wuqagtaunc(htblmsfkby) = udjatxewry kxziawlvpt (blwhskymdn, fwxdramnwz - hfoerqsnik) View more	-	08 Jun 2018
				MEDI8852+Oseltamivir (MEDI8852 750 mg + Oseltamivir 75 mg)	wuqagtaunc(htblmsfkby) = yxkfupkcqd kxziawlvpt (blwhskymdn, neyhkqpvtx - ctnmbkwess) View more
NCT02350751 (Pubmed \| Biologicals) Manual	Phase 1	Influenza A virus infection	40	MEDI8852	(aaokznegro) = No subjects discontinued the study due to a TEAE. xabipaldpw (umzsgaahbq )	Positive	01 Nov 2017
				Placebo

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data